Evidence map›Paper›PMID 30963203›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2019

Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience.

Anaïs Jouin, Sylvie Helfre, Stéphanie Bolle, Line Claude, Anne Laprie, Emilie Bogart, Céline Vigneron, Hélène Potet, Anne Ducassou, Audrey Claren and 6 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Anaïs JouinRadiotherapy department, Centre Oscar Lambret, Lille, France.
Sylvie HelfreRadiotherapy department, Institut Curie, Paris, France.
Stéphanie BolleGustave Roussy, Department of Radiotherapy Oncology, Université Paris-Saclay, 94805, Villejuif, France.
Line ClaudeRadiotherapy department, Centre Lyon Bérard, Lyon, France.
Anne LaprieRadiotherapy department, IUCT Oncopole, Toulouse, France.
Emilie BogartBiostatistics department, Centre Oscar Lambret, Lille, France.
Céline VigneronRadiotherapy department, Centre Paul Strauss, Strasbourg, France.
Hélène PotetRadiotherapy department, Centre Antoine Lacassagne, Nice, France.
Anne DucassouRadiotherapy department, IUCT Oncopole, Toulouse, France.
Audrey ClarenRadiotherapy department, Centre Antoine Lacassagne, Nice, France.
François Georges RietGustave Roussy, Department of Radiotherapy Oncology, Université Paris-Saclay, 94805, Villejuif, France.
Marie Pierre CastexPediatric department, Claudius Regaud Hospital, Toulouse, France.
Cécile Faure-ConterPediatric department, Centre Leon Bérard, Lyon, France.
Brice FresneauGustave Roussy-Grand Campus, Pediatric department, University Paris-Saclay, Villejuif, France.
Anne Sophie DefachellesPediatric department, Centre Oscar Lambret, Lille, France.
Daniel OrbachSIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with cancer), PSL Research University, French Pediatric Rare Tumor group (Fracture group), Institut Curie, 26, rue d'Ulm, 75005, Paris, France. daniel.orbach@curie.fr.ORCID http://orcid.org/0000-0002-2520-139X
Centre Oscar Lambret · FRCentre Antoine Lacassagne · FRCentre Léon Bérard · FRInstitut universitaire du cancer de Toulouse Oncopole · FRUniversité Paris-Saclay · FRInstitut Claudius Regaud · FRInstitut Curie · FRUniversité Paris Sciences et Lettres · FRUniversité Paris-Sud · FR

Funding

Enfants, cancers et Santé NA
6 · The paper itself

Abstract

purposeThe aim of this study was to retrospectively study survival and long-term morbidities of children with nasopharyngeal carcinoma (NPC) treated by induction chemotherapy and concurrent chemoradiation (CRT). The total dose of radiation was adapted to the response following neoadjuvant chemotherapy.

methodsChildren with non-metastatic NPC treated in France between 1999 and 2015 were retrospectively included in the study. The strategy combined neoadjuvant platinum-based chemotherapy, followed by adapted CRT to tumor response.

resultsIn total, 95 patients (median age 15 years [range, 7-23 years], male-to-female ratio 1.8) with undifferentiated NPC were included; 59% of patients had TNM stage IV. Intensity-modulated radiotherapy (IMRT) was delivered to 57 patients (60%), while the other patients were treated with conformal RT (3D-RT). After a median follow-up of 4.5 years [range, 3.6-5.5 years], 13 relapses and seven deaths had occurred. The 3‑year overall and relapse-free survival (RFS) were 94% [95% CI, 85-97%] and 86% [77-92%], respectively. The locoregional failure rate was 6% [95% CI, 2-14]. Long-term treatment-related sequelae of grade 2+ were reported by 37 (50%) patients; odynophagia was significantly reduced treated by IMRT vs. conventional 3D-RT (7% vs. 55%, p = 0.015). Using a reduction dose of 59.4 Gy, 54 Gy, and 45 Gy, respectively, to the primary, involved, and uninvolved neck nodes, after a favorable tumor response, was not associated with an increased locoregional failure rate.

conclusionsThe survival rates for NPC have been considerably improved by means of multimodal therapy, but long-term locoregional morbidity remains common. Use of IMRT may induce less residual odynophagia. Radiation dose reduction adapted to chemotherapy response does not have a negative impact on outcome. These findings support the use of an RT protocol adapted to the tumor response to neoadjuvant chemotherapy for a long-lasting improvement in the patient's quality of life.

Indexed as

Induction ChemotherapyAdolescentChemoradiotherapyChildCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesFranceHumansMaleNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm StagingRadiotherapy, Intensity-ModulatedRetrospective StudiesAdolescents—young adultsChemotherapyLong-term sequelaeNasopharyngeal carcinomaRadiotherapy

Identifiers

PMID30963203
OpenAlexW2939054768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.